HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

Huakang Biomedical Holdings Company Limited

Equities

8622

KYG4644W1069

Medical Equipment, Supplies & Distribution

Delayed Hong Kong S.E. Other stock markets 01:38:10 21/05/2024 pm IST			5-day change	1st Jan Change
0.103 ^HKD	0.00%		+10.75%	-3.74%

28/03	Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
25/03	Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	CI

Huakang Biomedical Holdings Company Limited Announces Change of Address of Head Office, Effect from 18 December 2023

December 15, 2023 at 04:42 pm IST

The board (the "Board") of directors of Huakang Biomedical Holdings Company Limited announced that with effect from 18 December 2023, the address of head office and principal place of business of the Company in Hong Kong will be changed to Room 04, 9 Floor, Kimberley House, 35-35A Kimberley Road, Tsim Sha Tsui, Kowloon, Hong Kong.

Latest news about Huakang Biomedical Holdings Company Limited

Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	25/03	CI
An unknown buyer acquired 15.59% stake in Huakang Biomedical Holdings Company Limited from Ever Charming Inc for HKD 3.2 million.	25/01	CI
Huakang Biomedical Holdings Company Limited Announces Change of Address of Head Office, Effect from 18 December 2023	15/12	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee	02/23/02	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	08/22/08	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	10/22/10	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	24/22/24	CI
Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021	04/22/04	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	09/21/09	CI
Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Nine Months Ended September 30, 2021	28/21/28	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/21/13	CI
Huakang Biomedical Holdings Company Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021	29/21/29	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 30, 2021	11/21/11	CI
Huakang Biomedical Holdings Company Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended March 31, 2021	29/21/29	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2020	25/21/25	CI
Huakang Biomedical Holdings Company Limited Provides Earnings Guidance for the Year Ended December 31, 2020	05/21/05	CI
Huakang Biomedical Holdings Company Limited Announces Management Changes	16/20/16	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	10/20/10	CI
Huakang Biomedical Holdings Company Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Nine Months Ended September 30, 2020	30/20/30	CI
Huakang Biomedical Holdings Company Limited Announces Management Changes	01/20/01	CI

Chart Huakang Biomedical Holdings Company Limited

Duration

Period

Chart Huakang Biomedical Holdings Company Limited

More charts

Company Profile

Huakang Biomedical Holdings Co Ltd is an investment holding company mainly engaged in the production and sales of in-vitro diagnostic reagents. The Company operates its business through two segments. The Biological Reagents and Auxiliary Reproductive Supplies and Equipment segment is engaged in the research and development, production, marketing and sales of in-vitro diagnostic reagents, including male infertility in vitro diagnostic reagents, parasite series detection reagents and Epstein-Barr (EB) virus detection reagents. The Segment is also engaged in the manufacture and sale of auxiliary reproductive supplies and devices. The Healthcare Products and Supplements segment is engaged in the sales of health products and supplements.

Sector

Medical Equipment, Supplies & Distribution

Calendar

18/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED	-3.74%	6.61M
BIOMÉRIEUX	-6.26%	12.23B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.93%	8.17B
DIASORIN S.P.A.	+7.10%	5.78B
LANTHEUS HOLDINGS, INC.	+30.16%	5.74B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.47%	4.24B
10X GENOMICS, INC.	-57.20%	2.97B
ANDON HEALTH CO., LTD.	+12.56%	2.73B
VITROLIFE AB	-4.67%	2.38B
MYRIAD GENETICS, INC.	+27.38%	2.26B

Diagnostic & Testing Substances